E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer

被引:19
作者
Hebbar, Mohamed [1 ]
Adenis, Antoine [2 ]
Revillion, Francoise [3 ]
Duhamel, Alain [4 ]
Romano, Olivier [1 ]
Truant, Stephanie [5 ]
Libersa, Christian [6 ]
Giraud, Claire [7 ]
Triboulet, Jean-Pierre [8 ]
Pruvot, Francois-Rene [5 ]
Peyrat, Jean-Philippe [3 ]
机构
[1] Univ Hosp, Dept Med Oncol, Lille, France
[2] Ctr Oscar Lambret, Dept Gastrointestinal Oncol, F-59020 Lille, France
[3] Ctr Oscar Lambret, Human Mol Oncol Lab, F-59020 Lille, France
[4] Univ Hosp, Dept Epidemiol & Biostat, Lille, France
[5] Univ Hosp, Dept Surg & Transplantat, Lille, France
[6] Univ Hosp, INSERM 9301, Clin Investigat Ctr, Lille, France
[7] Leonard de Vinci Ctr, Dept Med Oncol, Dechy, France
[8] Univ Hosp, Dept Gen & Digest Surg, Lille, France
关键词
E-selectin; Polymorphism; Prognosis; Colorectal cancer; Endothelial cells; SOLUBLE E-SELECTIN; COLON-CANCER; ADJUVANT TREATMENT; BREAST-CANCER; SHEAR-FLOW; ATHEROSCLEROSIS; FLUOROURACIL; METASTASIS; EXPRESSION; CARCINOMA;
D O I
10.1016/j.ejca.2009.03.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some host-related factors may predict the risk cf metastasis after surgery of colorectal cancer (CRC). The endothelial adhesion molecule E-selectin is implicated in the metastatic spread of CRC. We postulated that some polymorphisms within the E-selectin gene, especially the S128R polymorphism, may increase the risk of metastases by facilitating adhesion of tumour cells to the endothelium. We collected blood samples for DNA extraction from 264 patients treated for stage II or III CRC and from 310 healthy controls in order to assess three polymorphisms within the E-selectin gene (S128R, G98T and L554F) and one within the P-selectin gene (V640L) Genotypes were analysed by the allelic discrimination TaqMan real-time PCR assay. The S128R polymorphism was detected in 59 patients (22.3%) and was strictly correlated with the G98T polymorphism. In multivariate analysis, the S128R polymorphism was associated with shorter event-free survival (EFS) and overall survival (OS) in the whole population (EFS: P = .003, HR 1.82, 95% CI 1.23-2.70; OS: P < 10(-4), HR 4.31, 95% CI 2.46-10.99), in patients with stage II CRC(EFS: P = .04, HR 1.92, 95% CI 1.02-3.60; OS: P = .02, HR 4.44, 95% CI 1.16-17.03), and in patients with stage III CRC (EFS: P = .04, HR 1.68, 95% CI 1.01-2.80; OS: P = .001, HR 4.04, 95% CI 1.73-9.46). L554F and V640L polymorphisms had no prognostic value. The S128R polymorphism is a constitutional factor associated with a higher risk of relapse and death in patients treated for CRC. This polymorphism detection may permit better selection of patients suitable for adjuvant therapy, especially among those with stage II disease. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1871 / 1876
页数:6
相关论文
共 29 条
[1]   Carcinoma of the colon [J].
Adenis, A ;
Conroy, T ;
Lassen, P ;
Merrouche, Y ;
Monges, G ;
Rivoire, M ;
Rougier, P ;
Ruggieri-Pignon, S .
BRITISH JOURNAL OF CANCER, 2001, 84 :65-68
[2]   Role of S128R polymorphism of E-selectin in colon metastasis formation [J].
Alessandro, Riccardo ;
Seidita, Gregorio ;
Flugy, Anna Maria ;
Damiani, Francesca ;
Russo, Antonio ;
Corrado, Chiara ;
Colomba, Paolo ;
Gullotti, Lucia ;
Buettner, Reinhard ;
Bruno, Loredana ;
De Leo, Giacomo .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (03) :528-535
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]   Current issues in adjuvant treatment of stage II colon cancer [J].
Andre, Thierry ;
Sargent, Daniel ;
Tabernero, Josep ;
O'Connell, Michael ;
Buyse, Marc ;
Sobrero, Alberto ;
Misset, Jean-Louis ;
Boni, Corrado ;
de Gramont, Aimery .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (06) :887-898
[5]  
Auer Johann, 2003, Am J Pharmacogenomics, V3, P317, DOI 10.2165/00129785-200303050-00003
[6]   Inequity in colorectal cancer treatment and outcomes:: a population-based study [J].
Carsin, A-E ;
Sharp, L. ;
Cronin-Fenton, D. P. ;
Ceilleachair, A. O. ;
Comber, H. .
BRITISH JOURNAL OF CANCER, 2008, 99 (02) :266-274
[7]   Cancer survival in five continents: a worldwide population-based study (CONCORD) [J].
Coleman, Michel P. ;
Quaresma, Manuela ;
Berrino, Franco ;
Lutz, Jean-Michel ;
De Angelis, Roberto ;
Capocaccia, Riccardo ;
Baili, Paolo ;
Rachet, Bernard ;
Gatta, Gemma ;
Hakulinen, Timo ;
Micheli, Andrea ;
Sant, Milena ;
Weir, Hannah K. ;
Elwood, J. Mark ;
Tsukuma, Hideaki ;
Koifman, Sergio ;
Azevedo e Silva, Gulnar ;
Francisci, Silvia ;
Santaquilani, Mariano ;
Verdecchia, Arduino ;
Storm, Hans H. ;
Young, John L. .
LANCET ONCOLOGY, 2008, 9 (08) :730-756
[8]   Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much? [J].
Gill, S ;
Loprinzi, CL ;
Sargent, DJ ;
Thomé, SD ;
Alberts, SR ;
Haller, DG ;
Benedetti, J ;
Francini, G ;
Shepherd, LE ;
Seitz, JF ;
Labianca, R ;
Chen, W ;
Cha, SS ;
Heldebrant, MP ;
Goldberg, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1797-1806
[9]  
Hebbar M, 1998, CLIN CANCER RES, V4, P373
[10]  
Hebbar M, 1999, CLIN CANCER RES, V5, P1427